HIV Infection Clinical Trial
Official title:
Study of Patients With Known or Suspected Infection With Strongyloides Stercoralis
This study will explore faster and easier ways to detect infection with the intestinal
parasite Strongyloides stercoralis and learn more about the conditions under which it causes
serious disease. Ordinarily, the Strongyloides helminth (type of intestinal worm) causes
only few, if any, symptoms, but in people with weakened immunity it may be very serious, and
even deadly.
People between 5 and 80 years of age with known or suspected S. stercoralis infection, or
infection with another helminth, such as filariasis, that might cause a cross-reaction with
S. stercoralis may be eligible for this study.
Participants found to be infected with S. stercoralis will be treated with ivermectin,
thiabendazole, or albendazole. In addition, they will undergo the following tests and
procedures:
- Blood tests and stool samples: Samples will be collected before and after treatment to
check general health status and immune function, and to look for parasites in stool. Up
to 50 milliliters (10 teaspoons) of blood will be drawn in adults and up to 25 ml (5
teaspoons) in children.
- Skin tests: A test similar to those used for tuberculosis and allergies will be
conducted to determine if there is sensitization to products of the parasite. Such a
test might be used as a rapid method to diagnose the infection. About three drops of
several different antigens (proteins) are injected into the skin of the arm. After 15
to 20 minutes, the area is checked to see if a red spot has formed and, if so, the spot
is measured.
Status | Completed |
Enrollment | 650 |
Est. completion date | |
Est. primary completion date | May 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 8 Years to 80 Years |
Eligibility |
- INCLUSION CRITERIA: Age of 5 to 80 years and of either sex. Access to primary medical care provider outside of the NIH Ability to give written informed consent (for adults) and parental consent (for those under 18) Presence of known or suspected infection with Stronglyloides stercoralis, such as significant peripheral blood eosinophilia (greater than 1000 eosinophils/mm(3)) for which no other cause is apparent. Willingness to participate and provide blood for in vitro assays and serum storage. EXCLUSION CRITERIA: Less than 5 years of age Pregnancy is not a criterion for exclusion. |
N/A
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Neva FA. Biology and immunology of human strongyloidiasis. J Infect Dis. 1986 Mar;153(3):397-406. Review. — View Citation
Newton RC, Limpuangthip P, Greenberg S, Gam A, Neva FA. Strongyloides stercoralis hyperinfection in a carrier of HTLV-I virus with evidence of selective immunosuppression. Am J Med. 1992 Feb;92(2):202-8. — View Citation
Sato Y, Otsuru M, Takara M, Shiroma Y. Intradermal reactions in strongyloidiasis. Int J Parasitol. 1986 Feb;16(1):87-91. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01680094 -
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
|
Phase 1/Phase 2 |